The primary hyperparathyroidism and its complications: Substantiation of funding volume for hospital pharmacotherapy
Full Text (PDF)
Oksana Zakharova 1 * , Alisa Lobuteva 1 , Yanina Gribova 1 , Olga Krylova 2 , Zhanna Mironenkova 3 , Laysan Gabdulkhakova 4 , Maksim Belyavskiy 1
More Detail
1 Department of Organization and Economics of Pharmacy, I. M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, RUSSIA2 Department of Pharmacy, I. M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, RUSSIA3 Department of Medical and Pharmaceutical Commodity Science, Saint-Petersburg State Chemical Pharmaceutical University, Saint-Petersburg, RUSSIA4 Department of Pharmacy Management and Economics with a Course in Medical and Pharmaceutical Commodity Science, Bashkir State Medical University, Ufa, RUSSIA* Corresponding Author

Abstract

This study investigates factors influencing the cost of pharmacotherapy for primary hyperparathyroidism (PHPT) in a hospital setting to optimize therapeutic strategies and rationalize financing. The study was conducted from 2020 to 2023 and included 200 patients with PHPT from two hospitals in Moscow, Russia. The key aspects for analysis were demographic profiles, treatment methods, complications, and associated costs. The majority of patients (52.1%) were aged 60-74 years, while only 2.0% were aged 75 or older. The most frequently prescribed medications were cardiovascular drugs (33.5%) and vitamin supplements (25.1%). Colecalciferol (13.5%), bisoprolol (6.8%), and cinacalcet (4.9%) were the most common individual medications. The study revealed that the cost of conservative treatment without complications was twice that of surgical treatment. These models can aid in justifying and optimizing PHPT treatment financing in hospital settings. The findings highlight the importance of individualized treatment approaches and cost optimization strategies.

Keywords

License

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Article Type: Original Article

ELECTRON J GEN MED, Volume 21, Issue 6, December 2024, Article No: em616

https://doi.org/10.29333/ejgm/15713

Publication date: 11 Dec 2024

Article Views: 117

Article Downloads: 101

Open Access References How to cite this article